Loading...
•
Dec 31, 2021
89Bio Q4 2021 Earnings Report
89Bio reported Q4 2021 financial results and provided a corporate update.
Key Takeaways
89Bio reported positive topline data from its Phase 1b/2a NASH trial and closed enrollment in the Phase 2 ENTRIGUE trial in SHTG. The company's cash, cash equivalents, and short-term investments totaled $150.7 million as of December 31, 2021.
Reported positive topline results from cohort 7 in the Phase 1b/2a trial demonstrating the therapeutic utility of pegozafermin for NASH treatment.
ENLIVEN Phase 2b NASH trial is on track for topline data in the first half of 2023.
Closed enrollment in the Phase 2 ENTRIGUE trial of pegozafermin in SHTG patients, with topline data expected in the second quarter of 2022.
Pegozafermin significantly increased adiponectin (+87%) at week 20 compared to baseline.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...